The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer.
The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer.
复制标题
DOI：
10.1186/1757-2215-7-48
复制
发表时间：
2014-05-07
影响因子：
4
通讯作者：
DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT)
中科院分区：
文献类型：
--
作者：
Kobayashi M;Chiba A;Izawa H;Yanagida E;Okamoto M;Shimodaira S;Yonemitsu Y;Shibamoto Y;Suzuki N;Nagaya M;DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT)
尽管对初始化疗的完全反应率增加，但大多数晚期卵巢癌患者复发并死于疾病进展。基于树突状细胞（DC）的免疫疗法已被开发为用于产生抗肿瘤免疫的新策略，作为癌症治疗的一部分。本研究旨在评估DC治疗复发性卵巢癌（ROC）的可行性和临床效果。这项回顾性研究包括2007年3月至2013年8月期间在2家机构接受标准化疗，随后接受靶向合成肽的基于DC的免疫治疗的56名ROC患者。检查不良事件（AE）和临床反应。未观察到严重治疗相关AE。71%的入组患者产生了免疫应答。ROC诊断的中位生存时间（MST）为30.4个月，首次接种的中位生存时间为14.5个月。通过多变量考克斯比例风险分析，将接种前白蛋白水平≥4.0 g/dL和乳酸脱氢酶水平<200 IU/L确定为有意义的独立因素。白蛋白水平≥4.0和<4.0 g/dL的患者从首次接种开始的MST分别为19.9和11.6个月。相应的疾病控制率分别为36%和15%。我们的研究结果证明了基于DC的免疫治疗对ROC患者的可行性和潜在的临床有效性。此外，良好的营养状况可能是进一步临床效果的重要因素。
Despite the increased rate of complete response to initial chemotherapy, most patients with advanced ovarian cancer relapse and succumb to progressive disease. Dendritic cell (DC)-based immunotherapy has been developed as a novel strategy for generating antitumor immunity as part of cancer treatments. The present study aimed to assess the feasibility and clinical effects of DC therapy for recurrent ovarian cancer (ROC). This retrospective study included 56 ROC patients who initially received standard chemotherapy followed by DC-based immunotherapy targeting synthesized peptides at 2 institutions between March 2007 and August 2013. The adverse events (AEs) and clinical responses were examined. No serious treatment-related AEs were observed. Seventy one percent of the enrolled patients developed an immunologic response. The median survival time (MST) from ROC diagnosis was 30.4 months, and that from the first vaccination was 14.5 months. Albumin levels of ≥4.0 g/dL and lactate dehydrogenase levels of <200 IU/L before vaccination were identified as significant independent factors by multivariate Cox proportional hazard analysis. The MST from the first vaccination in patients with albumin levels of ≥4.0 and <4.0 g/dL were 19.9 and 11.6 months, respectively. The corresponding disease control rates were 36% and 15%, respectively. Our results demonstrated the feasibility and potential clinical effectiveness of DC-based immunotherapy for ROC patients. Additionally, a good nutritional status might be an important factor for further clinical effects.
登录
查看更多内容
影响因子：
7.5
作者：
Nakatsuka, S;Oji, Y;Aozasa, K
通讯作者：
Aozasa, K
影响因子：
2.8
作者：
Ding, Pei-Rong;An, Xin;Pan, Zhi-Zhong
通讯作者：
Pan, Zhi-Zhong
影响因子：
45.3
作者：
Berek, Jonathan;Taylor, Peyton;Nicodemus, Christopher F.
通讯作者：
Nicodemus, Christopher F.
影响因子：
4.7
作者：
Hall, Marcia;Rustin, Gordon
通讯作者：
Rustin, Gordon
影响因子：
5.8
作者：
Rahma, Osama E.;Ashtar, Ed;Czystowska, Malgorzata;Szajnik, Marta E.;Wieckowski, Eva;Bernstein, Sarah;Herrin, Vincent E.;Shams, Mortada A.;Steinberg, Seth M.;Merino, Maria;Gooding, William;Visus, Carmen;DeLeo, Albert B.;Wolf, Judith K.;Bell, Jeffrey G.;Berzofsky, Jay A.;Whiteside, Theresa L.;Khleif, Samir N.
通讯作者：
Khleif, Samir N.